Maite Bourlon: Adjuvant pembrolizumab is SOC for high-risk resected RCC
Maite Bourlon, the Head of the Urologic Oncology Clinic at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Editorial Board Member of OncoDaily, shared on X (Twitter):
“ASCO Daily News Proposed algorithm!
Adjuvant pembrolizumab is SOC for high-risk resected RCC
🔹Oligometastatic recurrence▶️ surveillance, surgery, radiation or ablative strategies
🔸Multifocal disease: refractory, early recurrence or late recurrence.
✅Treat accordingly”
Source: Maite Bourlon / X
Maria T Bourlon is an Associate Professor and Head of the Urologic Oncology Clinic at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico. She is the Director of the Genitourinary Cancers Program at Universidad Nacional Autónoma de México. Dr. Bourlon is the chair-elect of the American Society of Clinical Oncology IDEA Steering Group and in 2023 received the prestigious ASCO CCF International Women Who Conquer Cancer (WWCC) Mentorship Award. She is on the Editorial Board of OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023